LYEL (Lyell Immunopharma) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LYEL Lyell Immunopharma Inc LYEL
53 GF Score
Price $14.53
GF Value $3.71
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Lyell Immunopharma Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Lyell Immunopharma Quality Rank Related Terms

LYEL
53GF Score
Lyell Immunopharma Inc LYEL
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lyell Immunopharma (LYEL) Overvalued in 2026?

Based on GuruFocus' analysis, Lyell Immunopharma stock appears to be overvalued. The current stock price of $14.53 is trading 291.5% above its estimated GF Value™ of $3.71. GuruFocus considers Lyell Immunopharma to be Significantly Overvalued.

Key valuation signals for LYEL:

  • Quality Rank:
  • GF Value™: $3.71 vs. price of $14.53 (291.5% above fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the LYEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lyell Immunopharma Business Description

Address 201 Haskins Way, South San Francisco, CA, USA, 94080
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
53GF Score

Get the complete analysis for LYEL

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.53
Price
$3.71
GF Value